Interview released with Reckitt Benckiser, speaker at Pain Therapeutics 2019
SMi Group are delighted to host the exclusive conference on Pain Therapeutics on the 13th and 14th May 2019 in London, which will bring in expert voices from those at the forefront of technological innovation and analgesic therapies. The 2019 agenda features 15 insightful presentations from the industry leaders.
SMi's interview was with Dalma Sugár, Global Medical Affairs Director, Reckitt Benckiser.
Dalma is a senior medical leader with over 18 years of experience spanning pharmaceutical and consumer health industry, Rx and OTC, having a breadth and depth of experience with medical/clinical and regulatory/safety functions, from both strategic global and local perspective. She has built a career in a variety of roles, started in the governmental sector, then continued in Sanofi Group for 7 years also heading a clinical trial platform later as Regulatory Medical Head for the Sanofi Group leading a portfolio of oncology, cardiovascular, neuroscience, diabetes etc.
In 2012, Dalma joined Reckitt Benckiser as Regional Medical & Regulatory Affairs Head and from beginning of 2016 appointed as Global Medical Affairs Director at the Category Development organization.
The following are excerpts from Dalma's exclusive speaker interview with SMi
Q: The Pain Therapeutics market has matured greatly over recent years, what key differences have you noticed in the last year regarding significant developments?
A: "In the past decades there is an increasing incidence in chronic diseases such as nerve damage, joint pain, back pain, injuries, depression which coupled with increasing geriatric population and changing lifestyle are key factors in driving growth of the pain management therapeutics market. However, side effects caused by certain pain management therapeutics, availability of other generic pain management medications and increasing preference for them, are key factors restraining the growth of the global pain management therapeutics market."
Q: Where do you see the greatest opportunities for analgesic therapeutics leaders in 2019?
"Chronic pain is a major healthcare issue owing to its high prevalence, accompanied by significant physical and emotional burden on the patient and a significant financial burden on the society. It is the leading cause of years lost to disability. There is a huge unmet need for effective medications and innovative alternative solutions in this space, whether it be targeting the chronic pain sufferer itself or the better management of acute pain sufferer and therefore prevention of the chronification of their pain."
Q: Who are you most looking forward to hearing from at the main-conference and why?
A: "I am most looking forward to hearing from Donald Manning on his topic on Therapy for the disease of pain rather than nociceptive masking. I am very interested in learning more about his views on targeting the pathologic response to trauma or injury rather than protective nociception."
You can download the full speaker interview at http://www.pain-therapeutics.co.uk/PR3 just visit the website, download centre.
The two-day conference will showcase a dedicated focus on relevant issues; recent developments in Pain Therapeutics; in-depth case studies including elagolix for treatment of endometriosis pain; spotlight sessions on migraine therapy and 5-HT1F agonist lasmiditan by Eli Lily; a deep dive session on exploring new approaches and struggles to develop pain products; and more.
For those interested in attending, there is a £200 Early Bird discount on bookings expiring on Friday 29th March 2019. Places can be booked at http://www.pain-therapeutics.co.uk/PR3
Pain Therapeutics 2019 is proudly sponsored by CHDR, Lotus Clinical Research, MD Biosciences.
We have tailored sponsorship packages available, if you are interested contact Alia Malick, Director, on +44 (0) 20 827 6168 or email email@example.com
For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or firstname.lastname@example.org
Pain Therapeutics 2019
13 – 14 May
Copthorne Tara Hotel, London, UK
Follow us @SMiPharm
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Marketing Dept, 1st Floor
45 Curlew Street, London, SE1 2ND
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Interview released with Reckitt Benckiser, speaker at Pain Therapeutics 2019 here
News-ID: 1637204 • Views: 511
More Releases from SMi Group
Conference Chair from AstraZeneca invites you to attend Pre-filled Syringes East …
The 7th annual Pre-filled Syringes East Coast conference and exhibition is returning to Boston USA, in April. SMi Group are delighted to have Michael Song, Senior Manager, Dosage Form Design and Development, AstraZeneca chairing the two-day conference. Read the letter from the chair: Dear Colleagues, It is with great pleasure and delight that we welcome each of you to SMi's 7th annual Pre-Filled Syringes East conference in Boston, USA. Over the past decade, the
Registration Opens for Future Armoured Vehicles Weapon Systems 2020
SMi Group are pleased to announce the return of the Future Armoured Vehicles Weapon Systems conference, which will convene in London on the 3rd - 4th June 2020 for its fifth year. High level military personnel and industry leaders from around the globe will gather to gain insight on the latest developments in firepower capabilities and weapon systems for next generation armoured vehicles. Industry experts will provide an overview of cutting-edge
Estonian Defence Forces to give updates on their RAS Program at Military Robotic …
The 3rd Annual Military Robotics and Autonomous Systems (RAS) Conference, taking place on the 1st-2nd April 2020 in London, will provide essential insights into the development and implementation of unmanned and autonomous ground systems from the world's leading militaries. For those who would like to attend the conference, there is a 100 GBP early bird discount for bookings made by 28th February 2020. Register online at http://www.robotics-autonomous.com/openpr5
AI in Drug Discovery to host panel discussion on "The AI Paradigm Shift - is it …
SMi Reports: The AI in Drug Discovery conference will feature a panel discussion with panellists from Novartis, OMass Therapeutics, Domaineux and AstraZeneca. SMi Group's inaugural AI in Drug Discovery conference will take place on 16th-17th March 2020 in London to analyse and discuss AI machine learning technologies and their potential to reduce drug discovery costs by an estimated US$70 billion over the next decade. The conference will host a panel discussion
More Releases for Pain
Global Pain Management Drugs & Devices Market By Application - Burn Pain, Cancer …
Researchmoz added Most up-to-date research on "Global Pain Management Drugs & Devices Market By Application - Burn Pain, Cancer Pain, Dental/Facial Pain, Migraine Headache Pain & Musculoskeletal Pain" to its huge collection of research reports. This report studies Pain Management Drugs & Devices in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016,
Pain Management Devices Market
ReportsWorldwide has announced the addition of a new report title Pain Management Devices Market to its growing collection of premium market research reports. For a Detailed description and table of contents of this report please click here: https://www.reportsworldwide.com/report/pain-management-devices-market More than 100 million people in the US experience chronic pain. In Europe, the prevalence of chronic pain is between 25% and 35%. Pain-related disability represents a significant and costly liability to patients
Boot chronic pain
For immediate release Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue. We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them
Targeting chronic pain
With the support of the Austrian Science Fund FWF, the neurophysiologist Ruth Drdla-Schutting is investigating the role astrocytes play in the genesis of chronic pain. With the help of innovative gene technology (DREADDs), scientists are tailoring treatment specifically to these cells that are the most numerous found in the central nervous system. Pain is an important protection system of the human body. But when it becomes chronic, as it frequently
Complex Regional Pain Syndrome
“Complex Regional Pain Syndrome Global 2016 Clinical Trials Review, H2" provides an detailed overview of Complex Regional Pain Syndrome scenario. Report includes top line data relating on Complex Regional Pain Syndrome Global clinical trials scenario. This report on Complex Regional Pain Syndrome also includes an review of trial numbers as well as their ( Complex Regional Pain Syndrome ) average enrollment in uppermost/top countries which are conducted worldwide. Complex Regional
Orthovisc- No More Pain
Orthovisc is a Hyaluronan formulation which stands effective in curing the knee joint pain. Joint pain caused due to osteoarthritis often keeps away people from taking part or enjoying a lot of things physically. Suffering from knee pain can create a lot of troubles in the life of the person suffering from it. In medical science, osteoarthritis is considered one of the most dreaded diseases which create a lot of